| Literature DB >> 35742207 |
Chenwei Pan1, Huijuan Zhao2,3, Qiaoling Du4, Yong Xu1, Dajun Tian5, Shuo Xiao6, Haiyin Wang7, Xiao Wei8, Chunfeng Wu9, Yuanyuan Ruan10,11, Chunhua Zhao12,13, Gonghua Tao9, Weiwei Zheng2,3.
Abstract
BACKGROUND: Research indicates that exposure to polychlorinated biphenyls (PCBs) can cause neurobehavioral impairments in neonates and adults, but the way specific PCBs' congeners impact cognition functions at a low exposure level in a real-life co-exposure system remains poorly understood. This study aimed to investigate the association of PCBs burden with cognition function among elderly adults.Entities:
Keywords: Abbreviated Mental Test; cognitive dysfunction; older females; path analysis; polychlorinated biphenyls
Mesh:
Substances:
Year: 2022 PMID: 35742207 PMCID: PMC9222330 DOI: 10.3390/ijerph19126958
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 4.614
Figure 1Process of path analysis by structural equation modeling (SEM). (A) The hypothesis model of the exposure of 4 PCBs (PCB 28, PCB 101, PCB 138, and PCB 153), female participants’ CoD and confounders; (B) the direct effect of exposure to PCB 28 on CoD in female participants with ages below and equal to 80. * and blank line indicate p value < 0.05. The gray line indicates p value ≥ 0.05. Line thickness represents effect size (the thicker the line, the stronger the effect’s absolute value).
Participants characteristics (N = 266).
| Total | Normal | CoD a |
| |
|---|---|---|---|---|
| Age (years) d | 67 [63, 74] | 66 [63, 71] | 75 [65, 81] | <0.001 |
| Sex (%) | <0.001 | |||
| Male | 123 (46.2) | 111 (52.6) | 12 (21.8) | |
| Female | 143 (53.8) | 100 (47.4) | 43 (78.2) | |
| Education level (%) | <0.001 | |||
| Without formal education | 131 (49.2) | 89 (42.2) | 42 (76.4) | |
| Primary school | 106 (39.8) | 94 (44.5) | 12 (21.8) | |
| Middle school | 25 (9.4) | 24 (11.4) | 1 (1.8) | |
| High school | 4 (1.5) | 4 (1.9) | 0 (0.0) | |
| College | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Monthly income CNY (%) | 0.004 | |||
| ≤1 k | 166 (62.9) | 121 (57.9) | 45 (81.8) | |
| 1.01–3 k | 83 (31.4) | 74 (35.4) | 9 (16.4) | |
| >3 k | 15 (5.7) | 14 (6.7) | 1 (1.8) | |
| Living with spouse (%) | 0.058 | |||
| Without | 43 (16.2) | 29 (13.7) | 14 (25.5) | |
| With | 223 (83.8) | 182 (86.3) | 41 (74.5) | |
| Offspring (%) | 0.222 | |||
| No | 128 (48.1) | 97 (46.0) | 31 (56.4) | |
| Yes | 138 (51.9) | 114 (54.0) | 24 (43.6) | |
| Smoking status (%) | <0.001 | |||
| Never smoker | 171 (64.3) | 124 (58.8) | 47 (85.5) | |
| Current/former smoker | 95 (35.7) | 87 (41.2) | 8 (14.5) | |
| Habitual alcohol drinker (%) | 0.020 | |||
| No | 203 (76.3) | 154 (73.0) | 49 (89.1) | |
| Yes | 63 (23.7) | 57 (27.0) | 6 (10.9) | |
| Sleep quality (%) | 0.009 | |||
| poor | 28 (10.5) | 16 (7.6) | 12 (21.8) | |
| general | 35 (13.2) | 28 (13.3) | 7 (12.7) | |
| well | 203 (76.3) | 167 (79.1) | 36 (65.5) | |
| Sleep duration(h) d | 264 c | 210 c | 54 c | |
| 9.0 [8.0, 9.0] | 8.0 [8.0, 9.0] | 9.0 [8.0, 10.0] | <0.001 | |
| Headache (%) | 0.043 | |||
| No | 208 (78.2) | 171 (81.0) | 37 (67.3) | |
| Yes | 58 (21.8) | 40 (19.0) | 18 (32.7) | |
| Diabetes (%) | 0.057 | |||
| No | 241 (90.6) | 187 (88.6) | 54 (98.2) | |
| Yes | 25 (9.4) | 24 (11.4) | 1 (1.8) | |
| Hypertension (%) | 0.916 | |||
| No | 241 (90.6) | 187 (88.6) | 54 (98.2) | |
| Yes | 141 (53.0) | 111 (52.6) | 30 (54.5) | |
| AMT score d | 9.0 [8.0, 10.0] | 10.0 [8.0, 10.0] | 6.0 [5.0, 7.0] | <0.001 |
a: CoD = Cognitive dysfunction. b: p values were obtained from Mann-Whitney U test or chi-square test. c: two participants were missing in ‘Sleep duration’. d: median [IQR].
Plasma PCBs levels (ng/g lipid) of the participant sample (N =266).
| PCBs | Median [IQR] | Range | >MDL a (n) | >MDL (%) |
|---|---|---|---|---|
| PCB28 b | 8.95 [8.27, 10.10] | ND-127.07 | 37 | 13.91% |
| PCB52 b | 162.74 | ND-162.74 | 1 | 0.38% |
| PCB101 b | 11.30 [8.50, 16.10] | ND-247.46 | 110 | 41.35% |
| PCB138 c | 15.45 [8.60, 30.67] | ND-309.88 | 25 | 9.40% |
| PCB153 c | 10.96 [6.95, 15.92] | ND-283.12 | 22 | 8.27% |
| PCB180 c | 18.25 [5.68, 96.63] | ND-294.27 | 4 | 1.50% |
| 12.69 [8.91, 21.89] | ND-1424.54 | 140 | 52.63% |
a: MDL = method detection limit. The range is 4.02–9.72 ng/g lipid, which is reported for lipid-adjusted values. b: Lower-chlorination PCB congeners (LPCBs). c: Higher-chlorination congeners (HPCBs). d: means the sum of 6 indicator-PCBs (PCB28, 52, 101, 138, 153, and 180).
Association of Plasma PCB burden with cognitive impairment (N = 266).
| Number of | Model 0 a | Model 1 b | Model 2 c,e | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Variable | Normal | CoD | OR | 95% CI |
| OR | 95% CI |
|
| OR | 95% CI |
|
|
| PCB28 | |||||||||||||
| Not detected | 186 | 43 | 1.00 | - | ref | 1.00 | - | ref | 1.00 | - | ref | ||
| Detected | 25 | 12 | 2.08 | (0.94–4.39) | 0.061 | 2.92 | (1.23–6.81) | 0.014 | 0.041 | 3.12 | (1.19–8.11) | 0.019 | 0.171 |
| PCB101 | |||||||||||||
| Not detected | 121 | 35 | 1.00 | - | ref | 1.00 | - | ref | 1.00 | - | ref | ||
| Detected | 90 | 20 | 0.77 | (0.41–1.41) | 0.400 | 0.95 | (0.48–1.87) | 0.884 | 1.000 | 0.98 | (0.46–2.04) | 0.951 | 1.000 |
| PCB138 | |||||||||||||
| Not detected | 189 | 52 | 1.00 | - | ref | 1.00 | - | ref | 1.00 | - | ref | ||
| Detected | 22 | 3 | 0.50 | (0.11–1.50) | 0.269 | 0.46 | (0.1–1.56) | 0.261 | 0.782 | 0.53 | (0.10–2.00) | 0.391 | 1.000 |
| PCB153 | |||||||||||||
| Not detected | 191 | 53 | 1.00 | - | ref | 1.00 | - | ref | 1.00 | - | ref | ||
| Detected | 20 | 2 | 0.36 | (0.06–1.29) | 0.178 | 0.43 | (0.06–1.72) | 0.294 | 0.883 | 0.41 | (0.06–1.84) | 0.301 | 1.000 |
| LPCBs f | |||||||||||||
| Not detected | 101 | 25 | 1.00 | - | ref | 1.00 | - | ref | 1.00 | - | ref | ||
| Detected | 110 | 30 | 1.10 | (0.61–2.01) | 0.750 | 1.52 | (0.78–3.04) | 0.224 | 0.672 | 1.55 | (0.75–3.3) | 0.241 | 1.000 |
| HPCBs f | |||||||||||||
| Not detected | 175 | 52 | 1.00 | - | ref | 1.00 | - | ref | 1.00 | - | ref | ||
| Detected | 36 | 3 | 0.28 | (0.07–0.82) | 0.041 | 0.31 | (0.07–0.99) | 0.077 | 0.230 | 0.33 | (0.07–1.16) | 0.117 | 1.000 |
| ∑PCBs f | |||||||||||||
| Not detected | 101 | 25 | 1.00 | - | ref | 1.00 | - | ref | 1.00 | - | ref | ||
| Detected | 110 | 30 | 1.10 | (0.61–2.01) | 0.750 | 1.52 | (0.78–3.04) | 0.224 | 0.672 | 1.55 | (0.75–3.3) | 0.241 | 1.000 |
a: Model 0 was univariate logistic regression analysis. b: Model 1 was adjusted by age, sex. c: Model 2 was adjusted by covariates in model 1 and education level (formal education vs. without formal education), monthly income (≤1 k, 1.01–3 k, >3 k), marriage (living with a spouse vs. living without a spouse), offspring (yes vs. no), sleep quality (poor vs. general vs. well), sleep duration, and headache (yes vs. no). d: n = 264, two participants were missing in ‘Sleep duration’. e: p value was reported as Bonferroni-adjusted p value. f: LPCBs means lower-chlorination PCB congeners (PCB 28, 52, 101). HPCBs means higher-chlorination congeners (PCB 138, 153, 180). ∑PCBs means the 6 indicator PCBs (LPCBs: PCB 28, 52, and 101; HPCBs: PCB 138, 153, and 180).
Concentrations of PCBs in non-occupationally exposed populations from blood samples (ng/g Lipid) collected from other regions or countries.
| Country/Regions | Year | Sample | Median | Reference |
|---|---|---|---|---|
| China | ||||
| Weitang | 2015–2016 | Plasma | 12.7 a | this study |
| Weifang | 2012 | Serum | (7.1) b | [ |
| Weifang | 2014 | Serum | 11 c | [ |
| Yitong | 2014 | Serum | 15 c | [ |
| Lingshui | 2014 | Serum | 14 c | [ |
| Huaihua | 2014 | Serum | 10 c | [ |
| Ganzi | 2014 | Serum | 5.9 c | [ |
| Canada | 2011–2013 | Serum | 39.8 d | [ |
| US | 2005–2007 | Serum | 444.9 a | [ |
| US | 1999–2002 | Serum | 235 c | [ |
| UK | 2003 | Serum | 103.0 a | [ |
| Lebanon | 2018 | Serum | 18.9 a | [ |
| Iran | 2016–2017 | Serum | 344.6 a | [ |
| Japan | 2012 | Blood | 21.0 d | [ |
a: Sum of PCBs 28, 52 101,138, 153, 180. b: Sum of PCB 81, 77, 123, 118, 114, 105, 126, 167, 156, 157, 169, 170, 180 and 189. c: Sum of PCBs 77, 81, 101, 105, 114, 118, 123, 126, 156, 157, 167, 169, 170, 180, and 189. d: PCB153.